*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p><strong>Alvespimycin</strong> (17-AAG) is a semi-synthetic Hsp90 inhibitor derived from geldanamycin, utilized in oncology research. Its core synthesis involves chemical modification of the benzoquinone moiety to enhance solubility and pharmacokinetic profiles. Formula: C<sub>42</sub>H<sub>56</sub>N<sub>4</sub>O<sub>8</sub>; CAS No.: 39723-17-6.</p>
<h3>Application</h3>
<ul>
<li><strong>Oncology Research:</strong> Investigating synergistic effects with chemotherapy agents like docetaxel.</li>
<li><strong>Drug Development:</strong> Serving as a reference standard for heat shock protein inhibition studies.</li>
<li><strong>Biomarker Analysis:</strong> Evaluating tumor response mechanisms in preclinical models.</li>
</ul>
<h3>Precautions</h3>
<p>Restricted to investigational use only; not approved for clinical therapy. Requires storage at -20°C under inert atmosphere. Personnel must utilize PPE due to potential cytotoxicity and mutagenic risks associated with benzoquinone derivatives.</p>